No Data
No Data
WAI CHUN BIOTEC (00660) recommends implementing capital reduction and stock split.
WAI CHUN BIOTEC (00660) announced that the company proposes to implement the following capital restructuring involving capital reduction and share split as...
WAI CHUN BIOTEC (00660.HK) resumed trading this morning.
Gelonghui, December 23 - WAI CHUN BIOTEC (00660.HK) announced that the company's shares will resume trading today (23/12/2024) at 9:00 AM.
WAI CHUN BIOTEC (00660.HK) had an annual revenue of approximately 0.37 billion Hong Kong dollars, a year-on-year decrease of 52.2%.
Gelonghui, December 20th丨WAI CHUN BIOTEC (00660.HK) announced that for the year ending June 30, 2024, the group recorded revenue of approximately 370 million HKD, a decrease of 52.2% compared to the previous year. The decline in revenue is mainly attributed to weak market demand and reduced consumption of modified starch and other biochemical products during the reporting period. In addition, as part of the restructuring aimed at improving overall operational efficiency, the group has discontinued certain underperforming product lines. This decision has also contributed to the significant drop in revenue. The loss attributable to the company owners for the year ending June 30, 2024 is approximately 44.2 million HKD.
WAI CHUN BIOTEC: ANNUAL RESULTS FOR THE YEAR ENDED 30 JUNE 2024
Wai Chun Bio-Technology Forecasts Wider Loss for Year Ended June 30
Earnings warning: WAI CHUN BIOTEC (00660.HK) expects last year's losses to increase to between 57 million and 62 million.
WAI CHUN BIOTEC (00660.HK) has issued a profit warning, expecting to record a consolidated net loss ranging from 57 million to 62 million HKD for the year ending June 30, 2024, compared to a net loss of approximately 10 million HKD for the same period in 2023. The increase in net loss is attributed to a decrease in gross profit during the period and recognition of impairment losses on properties, plants, and equipment.
No Data